维力医疗 20250507 摘要 • 维力医疗通过持续的产品体系升级，包括麻醉、导尿等领域的新品推出， 如可视双腔插管、亲水涂层超滑导尿管等，不断提升产品竞争力及毛利率， 为公司盈利增长奠定基础。 • 公司通过分线营销改革，整合市场渠道和销售人员，优化营销团队结构， 尽管营销人员数量减少，但团队效率显著提升，营销费用率从 2021 年的 12.8%降至 2024 年的 10.5%，提高了盈利能力。 • 为保证供应链稳定，维力医疗在肇庆和墨西哥建厂扩产，提升产能和自动 化水平，规避地缘政治风险，节约运输和仓储成本，并计划在东南亚布局 第二个海外生产基地。 • 过去两年公司业绩受外销下滑（北美大客户去库存）和内销下降（国内医 院反腐）影响，但从 24 年 Q2 开始内销有所恢复，长期来看，这些因素有 助于改善行业经营秩序和竞争格局。 • 公司海外业务逐渐恢复增长，毛利率显著提升，主要归功于出口产品体系 升级，与客户合作的高端品类增多，海外毛利率从 2021 年的 27.1%提升 至 2024 年的 35.6%。 Q&A 维力医疗近年来的产品升级和研发投入情况如何？ 维力医疗近年来在产品升级和研发投入方面取得了显著 ...

根据《证券期货投资者适当性管理办法》及配套指引，本资料仅面向华创证券客户中的金融机构专业投资者，请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者，请勿订 阅、接收或使用本资料中的信息。 本资料难以设置访问权限，若给您造成不便，敬请谅解。感谢您的理解与配合。 摘要 产品体系升级是核心成长动力，研发、销售、制造全方位配套。 公司此前被看做传统低值耗材公司，但近年来产品升级已逐渐成为其核心成长动力，从 研发、营销到制造端，公司已为其产品体系升级的长期业务发展趋势做好全面配套。 过去两年受到外部因素干扰，产品升级成效未能完全体 现 | 一、 产品体系升级是核心成长动力,研发、销售、制造全方位配套 . | | --- | | (一) 研发:持续提高投入,产品管线不断升级 | | （二） 营销:国内营销改革成果显著,海外推进大客户定制化项目和本土化策略6 | | (三) 制造:国内肇庆建厂扩产,海外墨西哥建厂保障供应链稳定………………………………………………………… 7 | | 二、 过去两年受到外部因素干扰,产品升级成效未能完全体现 | | (一) 23年外销受到海外大客户去库存的影响 | | ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][9]. Core Views - The company is transitioning from low-cost to high-cost products, initiating a new phase of high growth despite facing external challenges in recent years [10][11]. - The overall profitability has significantly improved, with gross margins increasing from 43.2% in 2022 to 44.5% in 2024, despite revenue growth being impacted by external factors [2][41]. - Future growth is expected to be driven by the introduction of high-margin new products and the gradual reduction of the impact from anti-corruption measures in the domestic market [46][48]. Summary by Sections Product System Upgrade as Core Growth Driver - The company has focused on upgrading its product system across research, sales, and manufacturing, transitioning from a traditional low-value consumables company to a more innovative entity [15][16]. - R&D investment has increased from 0.42 billion in 2019 to 1.11 billion in 2024, with the R&D expense ratio rising from 4.3% to 7.4% [16][18]. Impact of External Factors on Performance - In 2023, external factors such as inventory destocking by overseas clients led to a decline in export revenue, which fell to 2.64 billion, a year-on-year decrease of 18% [1][31]. - Domestic sales were also affected by anti-corruption measures, resulting in a 15% year-on-year decline in the second half of 2023 [1][34]. Future Outlook and Margin Improvement - The report anticipates that the impact of anti-corruption will diminish, allowing for the accelerated introduction of high-margin new products, which will boost domestic sales and margins [46][48]. - The company is also expanding its overseas operations to mitigate geopolitical risks, with plans for new manufacturing facilities in Mexico and Southeast Asia [49][50]. Financial Forecast and Valuation - The projected total revenue for 2024 is 1.509 billion, with a year-on-year growth rate of 8.8%, and net profit is expected to reach 219 million, reflecting a 14% increase [4][12]. - The target price for the company's stock is set at 16 yuan, with a current price of 11.59 yuan, indicating significant upside potential [4][9].